Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib +/- Doxorubicin in Adenoid Cystic Carcinoma
NCT00077428Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2004
- Primary completion
- Jun 2007
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in adenoid cystic carcinoma (ACC), sponsored by National Cancer Institute. Started Jun 2004; status: completed.
02
Drugs
bortezomib
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT00077428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00077428.